Skip to main content
. Author manuscript; available in PMC: 2015 Jul 27.
Published in final edited form as: Cancer Clin Oncol. 2012 Nov;1(2):49–80. doi: 10.5539/cco.v1n2p49

Figure 10.

Figure 10

Collective cytotoxic anti-neoplastic potency of epirubicin-(C3-amide)-[anti-HER2/neu] or epirubicin-(C3-amide)-SS-[anti-HER2/neu] synthesized with an internal disulfide bond when each covalent anthracycline immunochemotherapeutic was applied in combination with griseofulvin. Legend: (◆) epirubicin-(C3-amide)-[anti-HER2/neu] in combination with griseofulvin (15 μM fixed concentration; and (■) epirubicin-(C3-amide)-SS-[anti-HER2/neu] in combination with griseofulvin (15 μM fixed concentration). Mammary adenocarcinoma (SKBr-3) monolayer populations were incubated with covalent epirubicin-immunochemotherapeutics in combination with benzimidazole for 72-hours and cytotoxicity measured as a function of MTT cell vitality stain intensity (absorbance at 570 nm) relative to matched negative reference controls.